Mason Carrico
Stock Analyst at Stephens & Co.
(3.60)
# 812
Out of 5,156 analysts
77
Total ratings
47.06%
Success rate
8.27%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Overweight | $197 → $235 | $205.22 | +14.51% | 6 | Nov 13, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $1.8 → $2 | $1.39 | +43.88% | 6 | Nov 10, 2025 | |
| HOLX Hologic | Downgrades: Equal-Weight | $78 → $76 | $75.59 | +0.54% | 6 | Oct 22, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $8.92 | +23.32% | 2 | Sep 2, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $34.12 | +96.37% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $124.28 | -15.51% | 8 | May 20, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $20.91 | -33.05% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $17.74 | +125.48% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $105.78 | +8.72% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $33.37 | +34.85% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $91.20 | -39.69% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $4.36 | +37.61% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $18.32 | -7.21% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $69.06 | -24.70% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $4.81 | +315.80% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $27.02 | +51.74% | 7 | Jan 2, 2025 |
Natera
Nov 13, 2025
Maintains: Overweight
Price Target: $197 → $235
Current: $205.22
Upside: +14.51%
Pacific Biosciences of California
Nov 10, 2025
Maintains: Overweight
Price Target: $1.8 → $2
Current: $1.39
Upside: +43.88%
Hologic
Oct 22, 2025
Downgrades: Equal-Weight
Price Target: $78 → $76
Current: $75.59
Upside: +0.54%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $8.92
Upside: +23.32%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $34.12
Upside: +96.37%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $124.28
Upside: -15.51%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $20.91
Upside: -33.05%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $17.74
Upside: +125.48%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $105.78
Upside: +8.72%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $33.37
Upside: +34.85%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $91.20
Upside: -39.69%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $4.36
Upside: +37.61%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $18.32
Upside: -7.21%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $69.06
Upside: -24.70%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $4.81
Upside: +315.80%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $27.02
Upside: +51.74%